600.3ºC at 760mmHg
HS Code Reference
Personal Projective Equipment
For Reference Standard and R&D, Not for Human Use Directly.
provides coniferyl ferulate(CAS#:483-18-1) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate
As of June 2020, the number of people infected with severe acute respiratory coronavirus 2 (SARS-CoV-2) continues to skyrocket, with more than 6.7 million cases worldwide. Both the World Health Organization (WHO) and United Nations (UN) has highlighted the need for better control of SARS-CoV-2 infections. However, developing novel virus-specific vaccines, monoclonal antibodies and antiviral drugs against SARS-CoV-2 can be time-consuming and costly. Convalescent sera and safe-in-man broad-spectrum antivirals (BSAAs) are readily available treatment options. Here, we developed a neutralization assay using SARS-CoV-2 strain and Vero-E6 cells. We identified the most potent sera from recovered patients for the treatment of SARS-CoV-2-infected patients. We also screened 136 safe-in-man broad-spectrum antivirals against the SARS-CoV-2 infection in Vero-E6 cells and identified nelfinavir, salinomycin, amodiaquine, obatoclax, emetine and homoharringtonine. We found that a combination of orally available virus-directed nelfinavir and host-directed amodiaquine exhibited the highest synergy. Finally, we developed a website to disseminate the knowledge on available and emerging treatments of COVID-19.
antiviral drug combinations; antivirals; broad-spectrum antivirals.
Potential Antiviral Options against SARS-CoV-2 Infection
Aleksandr Ianevski 1, Rouan Yao 1, Mona Høysæter Fenstad 2 3, Svetlana Biza 1, Eva Zusinaite 4, Tuuli Reisberg 5, Hilde Lysvand 1, Kirsti Løseth 1, Veslemøy Malm Landsem 1, Janne Fossum Malmring 2, Valentyn Oksenych 1, Sten Even Erlandsen 1, Per Arne Aas 1, Lars Hagen 1, Caroline H Pettersen 1, Tanel Tenson 4, Jan Egil Afset 1 2, Svein Arne Nordbø 1 2, Magnar Bjøras 1, Denis E Kainov 1 4
2020 Jun 13;
Does lopinavir really inhibit SARS-CoV-2?
Dario Cattaneo 1, Dario Cattaneo 2, Cristina Gervasoni 3, Mario Corbellino 4, Massimo Galli 4, Agostino Riva 4, Cristina Gervasoni 4, Emilio Clementi 5, Emilio Clementi 6
An escalating pandemic by the novel SARS-CoV-2 virus is impacting global health and effective therapeutic options are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estimated 50% effective concentration at 23.15 μM, 26.63 μM, 2.55 μM and 0.46 μM, respectively. Ribavirin or favipiravir that are currently evaluated under clinical trials showed no inhibition at 100 μM. Synergy between remdesivir and emetine was observed, and remdesivir at 6.25 μM in combination with emetine at 0.195 μM may achieve 64.9% inhibition in viral yield. Combinational therapy may help to reduce the effective concentration of compounds below the therapeutic plasma concentrations and provide better clinical benefits.
ABSTRACT; COVID-19; Emetine; Homoharringtonine; Lopinavir; Remdesivir; Ritonavir.
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
Ka-Tim Choy 1, Alvina Yin-Lam Wong 1, Prathanporn Kaewpreedee 1, Sin Fun Sia 1, Dongdong Chen 1, Kenrie Pui Yan Hui 1, Daniel Ka Wing Chu 1, Michael Chi Wai Chan 1, Peter Pak-Hang Cheung 2, Xuhui Huang 2, Malik Peiris 1, Hui-Ling Yen 3